Literature DB >> 34967034

Study on the material basis of Dahuang Zhechong pill of anti-hepatoma effect by promoting vascular normalization.

Honglin Chen1,2, Furong Yang1,2, Chuankui Fu1, Zimeng Zhang1, Kejia Xu1, Shengfeng Lu3, Zhipeng Chen4, Li Wu1,2, Weidong Li4.   

Abstract

Dahuang Zhechong Pill (DHZCP) is a traditional Chinese medicine prescription used to treat many diseases especially chronic liver disease accompanied by promotion of vascular normalization. In this work, UPLC-Q-TOF-MS/MS analysis was applied to identify the chemical components absorbed in the blood. HIF-1α, VEGF, Ang2 and Tie2 related to vascular normalization were detected to determine the dynamic changes of pharmacodynamic indicators. Then, the spectrum-effect relationship between the UHPLC fingerprint and pharmacodynamic indicators was evaluated dynamically using partial least squares (PLS). As a result, 103 components were identified from rat serum samples, including 56 original compounds and 47 metabolites. According to the PLS, active constituents of DHZCP acting on HIF-1α, VEGF, Ang2 and Tie2 (8, 15, 17 and 20) were found. In subsequent experiments on cells, 7/11 components of HIF-1α/VEGF were found in HepG2 and HUVEC cells, and 11/14/2 components of HIF-1α/VEGF/Tie2. The main pharmacodynamic components of DHZCP in promoting vascular normalization were successfully identified by the spectrum-effect relationship analysis.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Dahuang Zhechong Pill; UHPLC-Q-TOF-MS/MS; hepatocellular carcinoma; spectrum-effect relationship; vascular normalization

Mesh:

Substances:

Year:  2022        PMID: 34967034     DOI: 10.1002/bmc.5305

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  1 in total

1.  Investigating the Role of Dahuang in Hepatoma Treatment Using Network Pharmacology, Molecular Docking, and Survival Analysis.

Authors:  Bin Yu; Maoru Wang; Hui Xu; Rongrong Gao; Yuanying Zhu; Hong Ning; Xiaoyu Dai
Journal:  Biomed Res Int       Date:  2022-07-15       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.